BPC 157 is an exciting research peptide, showing significant potential as an anti-ulcer peptidergic and healing agent. Composed of 15 amino acids, BPC -157 is basically a partial sequence of human gastric juice called BPC or Body Protective Compound. It is also known as a “stable gastric pentadecapeptide”as it is found to remain stable in human gastric juices for at least 24 hours.
Scientific studies point out that BPC 157 has anti-ulcer peptidergic, healing and anti-inflammatory properties. Researchers believe that the peptide can play a crucial role in the treatment of various gastro-intestinal disorders . BPC-157 has been widely used to counter a variety of complications resulting from poorly controlled and advanced IBD. It has been found safe in clinical trials for inflammatory bowel disease and most importantly shows no reported toxicity. Inflammatory bowel disease (IBD) is a group of intestinal disorders that involves inflammation of the digestive tract.
Where BPC-157 helps?
- Inflammatory bowel disease (IBD)
— Ulcerative Colitis: a colon disorder characterized by the formation of ulcers and open sores
— Crohn’s Disease: chronic inflammation of the lining of the digestive tract, resulting in abdominal pain, diarrhea, fatigue and malnutrition.
— Esophagitis: inflammation of esophagus accompanied with increased difficulty in swallowing.
— Intestinal anastomosis healing (A process when a part of intestine is severed in a surgery and the two ends of the intestine are then surgically connected together)
- Short bowel syndrome 
- Fistula healing 
- NSAID induced GI damage 
How BPC 157 Works
BPC-157 shows tremendous cytoprotective characteristics and maintains the integrity of gastric mucosa. Cytoprotection is the ability of a pharmacological agent to reduce or prevent gastric mucosal damage induced by ulcerogenic agents. The most prominent feature here is that a cytoprotective agent works against ulcers not by inhibiting the secretion of gastric acid but by providing increased protection to the gastric mucosa.
BPC-157 also reduces inflammation and encourages healing all through the digestive tract, a process that plays an absolutely critical role in inflammatory bowel disease. The protective peptide achieves efficient wound healing by protecting the endothelium and promoting angiogenesis, a process where existing blood vessels sprout new blood vessels on the wound surface. Adequate angiogenic response enables enhanced delivery of oxygen and nutrients to the damaged tissue. This helps the damaged tissue to repair and heal faster.
The peptide also reduces the concentration of inflammatory mediators at the site of injury, helping further in the healing and regeneration of the damaged tissue. A 2009 research showed that the angiogenic potential of BPC 157 is derived from its ability to upregulate the expression of Vaso Endothelial Growth Factor (VEGF) . VEGF is a signalling protein that promotes the growth of new blood vessels after injury to restore blood and nutrients supply to damaged tissues with restricted blood circulation.
- Sikiric et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011
- Sever, M., Klicek, R., Radic, B. et al. Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats. Digestive Diseases and Sciences. October 2009, Volume 54, Issue 10, pp 2070–2083
- Cesarec V, Becejac T, Misic M, Djakovic Z, Olujic D, Drmic D, Brcic L, Rokotov DS, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. European Journal of Pharmacology. 2013
- P Sikiric et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. http://www.ncbi.nlm.nih.gov/pubmed/22950504. Current Pharmaceutical Design. 2013
- L. Brcic et al. Modulatory Effect Of Gastric Pentadecapeptide Bpc 157 On Angiogenesis In Muscle And Tendon Healing. Journal of Physiology And Pharmacology 2009